;PMID: 10515185
;source_file_2880.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..135] = [t:47..135]
;2)section:[e:139..201] = [t:139..201]
;3)section:[e:205..288] = [t:205..288]
;4)sentence:[e:292..386] = [t:292..386]
;5)sentence:[e:387..544] = [t:387..544]
;6)sentence:[e:545..790] = [t:545..790]
;7)sentence:[e:791..942] = [t:791..942]
;8)sentence:[e:943..1151] = [t:943..1151]
;9)sentence:[e:1152..1274] = [t:1152..1274]
;10)sentence:[e:1275..1358] = [t:1275..1358]
;11)section:[e:1362..1407] = [t:1362..1407]

;section 0 Span:0..41
;Neurosci Lett.  1999 Oct 8;273(3):167-70.
(SEC
  (FRAG (NNP:[0..8] Neurosci) (NNP:[9..13] Lett) (.:[13..14] .)
        (CD:[16..20] 1999) (NNP:[21..24] Oct) (CD:[25..26] 8) (::[26..27] ;)
        (CD:[27..30] 273) (-LRB-:[30..31] -LRB-) (CD:[31..32] 3)
        (-RRB-:[32..33] -RRB-) (::[33..34] :) (CD:[34..40] 167-70)
        (.:[40..41] .)))

;sentence 1 Span:47..135
;Characterization of a putative calcitonin receptor in IMR 32 human
;neuroblastoma  cells.
;[78..97]:gene-protein:"calcitonin receptor"
;[114..127]:malignancy-type:"neuroblastoma"
(SENT
  (NP-HLN
    (NP (NN:[47..63] Characterization))
    (PP (IN:[64..66] of)
      (NP (DT:[67..68] a) (JJ:[69..77] putative)
         (NN:[78..88] calcitonin) (NN:[89..97] receptor)))
    (PP-LOC (IN:[98..100] in)
      (NP
        (NML (NN:[101..104] IMR) (CD:[105..107] 32))
        (JJ:[108..113] human) (NN:[114..127] neuroblastoma)
         (NNS:[129..134] cells)))
    (.:[134..135] .)))

;section 2 Span:139..201
;Spampinato S, Falcucci B, Cacciaguerra S, Campana G, Murari G.
(SEC
  (FRAG (NNP:[139..149] Spampinato) (NNP:[150..151] S) (,:[151..152] ,)
        (NNP:[153..161] Falcucci) (NNP:[162..163] B) (,:[163..164] ,)
        (NNP:[165..177] Cacciaguerra) (NNP:[178..179] S) (,:[179..180] ,)
        (NNP:[181..188] Campana) (NNP:[189..190] G) (,:[190..191] ,)
        (NNP:[192..198] Murari) (NNP:[199..200] G) (NNP:[200..201] .)))

;section 3 Span:205..288
;Department of Pharmacology, University of Bologna, Italy. 
;spampi@biocfarm.unibo.it
(SEC
  (FRAG (NNP:[205..215] Department) (IN:[216..218] of)
        (NNP:[219..231] Pharmacology) (,:[231..232] ,)
        (NNP:[233..243] University) (IN:[244..246] of) (NNP:[247..254] Bologna)
        (,:[254..255] ,) (NNP:[256..261] Italy) (.:[261..262] .)
        (NN:[264..288] spampi@biocfarm.unibo.it)))

;sentence 4 Span:292..386
;In this study we characterized calcitonin (CT) receptors in human
;neuroblastoma  IMR 32 cells.
;[323..348]:gene-protein:"calcitonin (CT) receptors"
;[358..371]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (PP (IN:[292..294] In)
      (NP (DT:[295..299] this) (NN:[300..305] study)))
    (NP-SBJ (PRP:[306..308] we))
    (VP (VBD:[309..322] characterized)
      (NP
        (NP
          (NML
            (NML (NN:[323..333] calcitonin))
            (NML (-LRB-:[334..335] -LRB-) (NN:[335..337] CT)
                 (-RRB-:[337..338] -RRB-)))
          (NNS:[339..348] receptors))
        (PP-LOC (IN:[349..351] in)
          (NP (JJ:[352..357] human) (NN:[358..371] neuroblastoma)
            (NML (NN:[373..376] IMR) (CD:[377..379] 32))
            (NNS:[380..385] cells)))))
    (.:[385..386] .)))

;sentence 5 Span:387..544
;Saturation binding assays indicated that [125I]-human CT bound  with high
;affinity to IMR 32 cell membranes (K(d) = 253.6 pM; Bmax = 3.84 fmol/  mg
;protein).
;[441..443]:gene-protein:"CT"
(SENT
  (S
    (NP-SBJ (NN:[387..397] Saturation) (NN:[398..405] binding)
            (NNS:[406..412] assays))
    (VP (VBD:[413..422] indicated)
      (SBAR (IN:[423..427] that)
        (S
          (NP-SBJ
            (ADJP (NN:[428..434] -LSB-125I-RSB-) (HYPH:[434..435] -)
                  (JJ:[435..440] human))
            (NN:[441..443] CT))
          (VP (VBD:[444..449] bound)
            (PP (IN:[451..455] with)
              (NP (JJ:[456..460] high) (NN:[461..469] affinity)))
            (PP-CLR (TO:[470..472] to)
              (NP
                (NML (NN:[473..476] IMR) (CD:[477..479] 32))
                (NN:[480..484] cell) (NNS:[485..494] membranes)))
            (PRN (-LRB-:[495..496] -LRB-)
              (S
                (NP-SBJ (NN:[496..500] K-LRB-d-RRB-))
                (VP (SYM:[501..502] =)
                  (NP (CD:[503..508] 253.6) (NN:[509..511] pM))))
              (::[511..512] ;)
              (S
                (NP-SBJ (NN:[513..517] Bmax))
                (VP (SYM:[518..519] =)
                  (NP
                    (NP (CD:[520..524] 3.84) (NN:[525..529] fmol))
                    (PP (SYM:[529..530] /)
                      (NP (NN:[532..534] mg) (NN:[535..542] protein)))))
                (-RRB-:[542..543] -RRB-)))))))
    (.:[543..544] .)))

;sentence 6 Span:545..790
;In competition binding studies, human adrenomedullin displayed high  affinity
;for these sites (IC50 = 30 nM) whereas human alpha calcitonin-gene  related
;peptide (alphaCGRP; IC50 = 145 nM) and human amylin (IC50 = 415 nM)  showed
;lower affinity.
;[583..597]:gene-protein:"adrenomedullin"
;[668..706]:gene-protein:"alpha calcitonin-gene  related peptide"
;[708..717]:gene-protein:"alphaCGRP"
;[744..750]:gene-protein:"amylin"
(SENT
  (S
    (PP (IN:[545..547] In)
      (NP (NN:[548..559] competition) (NN:[560..567] binding)
          (NNS:[568..575] studies)))
    (,:[575..576] ,)
    (NP-SBJ (JJ:[577..582] human) (NN:[583..597] adrenomedullin))
    (VP (VBD:[598..607] displayed)
      (NP
        (NP (JJ:[608..612] high) (NN:[614..622] affinity))
        (PP (IN:[623..626] for)
          (NP (DT:[627..632] these) (NNS:[633..638] sites)))
        (PRN (-LRB-:[639..640] -LRB-)
          (S
            (NP-SBJ (NN:[640..644] IC50))
            (VP (SYM:[645..646] =)
              (NP (CD:[647..649] 30) (NN:[650..652] nM)))
            (-RRB-:[652..653] -RRB-))))
      (SBAR-ADV (IN:[654..661] whereas)
        (S
          (NP-SBJ
            (NP (JJ:[662..667] human)
              (NML
                (NML
                  (ADJP
                    (NML
                      (NML (SYM:[668..673] alpha) (NN:[674..684] calcitonin))
                      (HYPH:[684..685] -) (NN:[685..689] gene))
                    (VBN:[691..698] related))
                  (NN:[699..706] peptide))
                (NML (-LRB-:[707..708] -LRB-) (NN:[708..717] alphaCGRP)
                     (::[717..718] ;)))
              (PRN
                (S
                  (NP-SBJ (NN:[719..723] IC50))
                  (VP (SYM:[724..725] =)
                    (NP (CD:[726..729] 145) (NN:[730..732] nM)))
                  (-RRB-:[732..733] -RRB-))))
            (CC:[734..737] and)
            (NP (JJ:[738..743] human) (NN:[744..750] amylin)
              (PRN (-LRB-:[751..752] -LRB-)
                (S
                  (NP-SBJ (NN:[752..756] IC50))
                  (VP (SYM:[757..758] =)
                    (NP (CD:[759..762] 415) (NN:[763..765] nM)))
                  (-RRB-:[765..766] -RRB-)))))
          (VP (VBD:[768..774] showed)
            (NP (JJR:[775..780] lower) (NN:[781..789] affinity))))))
    (.:[789..790] .)))

;sentence 7 Span:791..942
;These peptides increased cAMP levels in viable cells; the  relative potencies
;were: human CT > human adrenomedullin > human cCGRP > or =  human amylin.
;[881..883]:gene-protein:"CT"
;[892..906]:gene-protein:"adrenomedullin"
;[915..920]:gene-protein:"cCGRP"
;[935..941]:gene-protein:"amylin"
(SENT
  (S
    (S
      (NP-SBJ (DT:[791..796] These) (NNS:[797..805] peptides))
      (VP (VBD:[806..815] increased)
        (NP (NN:[816..820] cAMP) (NNS:[821..827] levels))
        (PP-LOC (IN:[828..830] in)
          (NP (JJ:[831..837] viable) (NNS:[838..843] cells)))))
    (::[843..844] ;)
    (S
      (NP-SBJ (DT:[845..848] the) (JJ:[850..858] relative)
              (NNS:[859..868] potencies))
      (VP (VBD:[869..873] were) (::[873..874] :)
        (NP-PRD
          (NP (JJ:[875..880] human) (NN:[881..883] CT))
          (PP (SYM:[884..885] >)
            (NP
              (NP (JJ:[886..891] human) (NN:[892..906] adrenomedullin))
              (PP (SYM:[907..908] >)
                (NP
                  (NP (JJ:[909..914] human) (NN:[915..920] cCGRP))
                  (PP (SYM:[921..922] >) (CC:[923..925] or) (SYM:[926..927] =)
                    (NP (JJ:[929..934] human) (NN:[935..941] amylin))))))))))
    (.:[941..942] .)))

;sentence 8 Span:943..1151
;The expression of mRNA coding for the published sequences of the  human
;calcitonin receptor and of the human calcitonin receptor-like receptorwas 
;evaluated by reverse transcriptase-polymerase chain reaction.
;[1015..1034]:gene-protein:"calcitonin receptor"
;[1052..1071]:gene-protein:"calcitonin receptor"
;[1103..1124]:gene-protein:"reverse transcriptase"
;[1125..1135]:gene-protein:"polymerase"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[943..946] The) (NN:[947..957] expression))
      (PP (IN:[958..960] of)
        (NP
          (NP (NN:[961..965] mRNA) (NN:[966..972] coding))
          (PP (IN:[973..976] for)
            (NP
              (NP (DT:[977..980] the) (VBN:[981..990] published)
                  (NNS:[991..1000] sequences))
              (PP
                (PP (IN:[1001..1003] of)
                  (NP (DT:[1004..1007] the) (JJ:[1009..1014] human)
                     (NN:[1015..1025] calcitonin) (NN:[1026..1034] receptor)))
                (CC:[1035..1038] and)
                (PP (IN:[1039..1041] of)
                  (NP (DT:[1042..1045] the) (JJ:[1046..1051] human)
                    (ADJP
                      (NML (NN:[1052..1062] calcitonin)
                           (NN:[1063..1071] receptor))
                      (HYPH:[1071..1072] -) (JJ:[1072..1076] like))
                    (NN:[1077..1085] receptor)))))))))
    (VP (VBD:[1085..1088] was)
      (VP (VBN:[1090..1099] evaluated)
        (NP-1 (-NONE-:[1099..1099] *))
        (PP-MNR (IN:[1100..1102] by)
          (NP
            (NML (JJ:[1103..1110] reverse) (NN:[1111..1124] transcriptase))
            (HYPH:[1124..1125] -) (NN:[1125..1135] polymerase)
             (NN:[1136..1141] chain) (NN:[1142..1150] reaction)))))
    (.:[1150..1151] .)))

;sentence 9 Span:1152..1274
;Electrophoretic  analysis did not confirm the occurrence of mRNA coding for
;the above mentioned  receptors in these cells.
(SENT
  (S
    (NP-SBJ (JJ:[1152..1167] Electrophoretic) (NN:[1169..1177] analysis))
    (VP (VBD:[1178..1181] did) (RB:[1182..1185] not)
      (VP (VB:[1186..1193] confirm)
        (NP
          (NP (DT:[1194..1197] the) (NN:[1198..1208] occurrence))
          (PP (IN:[1209..1211] of)
            (NP (NN:[1212..1216] mRNA) (NN:[1217..1223] coding))))
        (PP (IN:[1224..1227] for)
          (NP (DT:[1228..1231] the)
            (ADJP (RB:[1232..1237] above) (VBN:[1238..1247] mentioned))
            (NNS:[1249..1258] receptors)))
        (PP-LOC (IN:[1259..1261] in)
          (NP (DT:[1262..1267] these) (NNS:[1268..1273] cells)))))
    (.:[1273..1274] .)))

;sentence 10 Span:1275..1358
;This study suggests the presence of a novel, putative  CT receptor in IMR 32
;cells.
;[1330..1341]:gene-protein:"CT receptor"
(SENT
  (S
    (NP-SBJ (DT:[1275..1279] This) (NN:[1280..1285] study))
    (VP (VBZ:[1286..1294] suggests)
      (NP
        (NP (DT:[1295..1298] the) (NN:[1299..1307] presence))
        (PP (IN:[1308..1310] of)
          (NP (DT:[1311..1312] a) (JJ:[1313..1318] novel) (,:[1318..1319] ,)
              (JJ:[1320..1328] putative)
             (NN:[1330..1332] CT) (NN:[1333..1341] receptor)))
        (PP-LOC (IN:[1342..1344] in)
          (NP
            (NML (NN:[1345..1348] IMR) (CD:[1349..1351] 32))
            (NNS:[1352..1357] cells)))))
    (.:[1357..1358] .)))

;section 11 Span:1362..1407
;PMID: 10515185 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1362..1366] PMID) (::[1366..1367] :) (CD:[1368..1376] 10515185)
        (NN:[1377..1378] -LSB-) (NNP:[1378..1384] PubMed) (::[1385..1386] -)
        (NN:[1387..1394] indexed) (IN:[1395..1398] for)
        (NNP:[1399..1406] MEDLINE) (-RRB-:[1406..1407] -RSB-)))
